Eric J Miller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8932844/publications.pdf

Version: 2024-02-01

		1040056	1125743
13	202	9	13
papers	citations	h-index	g-index
13	13	13	389
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018. Expert Opinion on Therapeutic Patents, 2020, 30, 87-101.	5.0	32
2	A Real-Time Method for Measuring cAMP Production Modulated by G <i>α</i> _{i/o} -Coupled Metabotropic Glutamate Receptors. Journal of Pharmacology and Experimental Therapeutics, 2014, 349, 373-382.	2.5	30
3	Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. Journal of Medicinal Chemistry, 2018, 61, 7168-7188.	6.4	22
4	Discovery of a Fluorinated Enigmol Analog with Enhanced in Vivo Pharmacokinetic and Anti-Tumor Properties. ACS Medicinal Chemistry Letters, 2016, 7, 537-542.	2.8	20
5	Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties. Journal of Medicinal Chemistry, 2018, 61, 946-979.	6.4	19
6	The Bioactive Protein-Ligand Conformation of GluN2C-Selective Positive Allosteric Modulators Bound to the NMDA Receptor. Molecular Pharmacology, 2018, 93, 141-156.	2.3	18
7	Chloride is an Agonist of Group II and III Metabotropic Glutamate Receptors. Molecular Pharmacology, 2015, 88, 450-459.	2.3	15
8	Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 Antagonists. ACS Medicinal Chemistry Letters, 2018, 9, 17-22.	2.8	13
9	Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains. ACS Medicinal Chemistry Letters, 2018, 9, 89-93.	2.8	12
10	Discovery of N-Alkyl Piperazine Side Chain Based CXCR4 Antagonists with Improved Drug-like Properties. ACS Medicinal Chemistry Letters, 2018, 9, 446-451.	2.8	9
11	ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties. Journal of Medicinal Chemistry, 2021, 64, 12917-12937.	6.4	8
12	Amino-Heterocycle Tetrahydroisoquinoline CXCR4 Antagonists with Improved ADME Profiles via Late-Stage Buchwald Couplings. ACS Medicinal Chemistry Letters, 2021, 12, 1605-1612.	2.8	3
13	Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles. Journal of Medicinal Chemistry, 2022, 65, 4058-4084.	6.4	1